Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer
- PMID: 16528377
- DOI: 10.1038/modpathol.3800570
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer
Abstract
Basal-like carcinomas have recently been identified in gene expression profiling studies as a subtype of invasive breast cancer. These lesions are estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative (triple negative), and typically express basal cytokeratins, epidermal growth factor receptor (EGFR), and/or c-kit. As poorly differentiated invasive ductal carcinomas, they presumably have a ductal carcinoma in situ (DCIS) precursor with similar cytologic and immunophenotypic features. However, the frequency and even the existence of a DCIS lesion with an immunophenotype analogous to that of invasive basal-like carcinomas have not been previously evaluated. We studied 66 cases of high nuclear grade DCIS using antibodies to ER, PR, HER2, three basal cytokeratins, EGFR, and c-kit to determine the frequency of the triple negative phenotype, and to determine the relationship between the triple negative phenotype and expression of basal cytokeratins and other biomarkers characteristically expressed by invasive basal-like carcinomas. Four cases (6%) exhibited the triple negative phenotype; the remaining cases showed other combinations of ER, PR, and HER2 expression (nontriple negative). Basal cytokeratins, EGFR, or both were expressed by all four triple negative lesions, but by only 21 of 51 (42%) nontriple negative cases (P = 0.04). We conclude that a small proportion of high-grade ductal carcinomas in situ exhibit an ER-negative/PR-negative/HER2-negative (triple negative) phenotype, and these lesions more commonly show expression of basal cytokeratins and/or EGFR than nontriple negative high-grade DCIS. Given that invasive breast cancers typically share immunophenotypic features with the ductal carcinoma in situ from which they arise, our findings raise the possibility that the triple-negative, basal cytokeratin and/or EGFR-positive DCIS lesions we identified represent a precursor lesion to invasive basal-like carcinomas.
Similar articles
-
Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.Mod Pathol. 2006 Nov;19(11):1506-11. doi: 10.1038/modpathol.3800678. Epub 2006 Aug 25. Mod Pathol. 2006. PMID: 16941011
-
Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.Jpn J Clin Oncol. 2012 May;42(5):375-86. doi: 10.1093/jjco/hys034. Epub 2012 Mar 26. Jpn J Clin Oncol. 2012. PMID: 22450930
-
Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.Ann Clin Lab Sci. 2007 Spring;37(2):127-34. Ann Clin Lab Sci. 2007. PMID: 17522367
-
In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.Tumour Biol. 2013 Feb;34(1):1-7. doi: 10.1007/s13277-012-0602-1. Epub 2012 Dec 4. Tumour Biol. 2013. PMID: 23208673 Review.
-
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.
Cited by
-
Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer.Radiol Oncol. 2011 Jun;45(2):123-8. doi: 10.2478/v10019-011-0014-7. Epub 2011 Apr 23. Radiol Oncol. 2011. PMID: 22933945 Free PMC article.
-
Harnessing the Immunogenic Potential of Gold Nanoparticle-Based Platforms as a Therapeutic Strategy in Breast Cancer Immunotherapy: A Mini Review.Front Immunol. 2022 Mar 31;13:865554. doi: 10.3389/fimmu.2022.865554. eCollection 2022. Front Immunol. 2022. PMID: 35432376 Free PMC article. Review.
-
Prognostic role of immune infiltrates in breast ductal carcinoma in situ.Breast Cancer Res Treat. 2019 Aug;177(1):17-27. doi: 10.1007/s10549-019-05272-2. Epub 2019 May 27. Breast Cancer Res Treat. 2019. PMID: 31134489 Review.
-
Biomarkers in triple negative breast cancer: A review.World J Clin Oncol. 2015 Dec 10;6(6):252-63. doi: 10.5306/wjco.v6.i6.252. World J Clin Oncol. 2015. PMID: 26677438 Free PMC article. Review.
-
Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017. Onco Targets Ther. 2017. PMID: 28435291 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
